Database administrator

Horizon3.ai Unveils Phishing Impact Testing to Help Organizations Understand the Impact of Phished Credentials

Retrieved on: 
Wednesday, February 7, 2024
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Multimedia, Principal, Frustration, Knowledge, Human, Learning, JavaScript, Risk, UI, Credential, Database administrator, Information security, Business, Organization, Online shopping

Horizon3.ai , a pioneer in autonomous security solutions, today announced the launch of its first-to-market Phishing Impact testing capability within NodeZero™.

Key Points: 
  • Horizon3.ai , a pioneer in autonomous security solutions, today announced the launch of its first-to-market Phishing Impact testing capability within NodeZero™.
  • This new capability marks a significant advancement in penetration testing, addressing a critical gap in understanding the real-world implications of phished credentials.
  • The Phishing Impact test delivered by NodeZero can help those IT and security teams accurately convey the “blast radius” of those phished credentials, proving that sensitive data was indeed at risk.
  • Horizon3.ai's Phishing Impact testing with NodeZero is a first-of-its-kind tool, equipping organizations with the knowledge and resources to proactively address vulnerabilities in their cybersecurity defenses.

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

Retrieved on: 
Monday, October 17, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Colon, Therapy, Neoplasm, EMA, Hyponatremia, NASDAQ, Antibody, Lymphocytopenia, SD, University, Abdominal distension, Primary sclerosing cholangitis, Association, Pseudomyxoma peritonei, CEO, Toxic leukoencephalopathy, University of California, San Francisco, Mesothelioma, UCSF, Database administrator, Population, Data, HIV disease progression rates, Cancer, Private Securities Litigation Reform Act, TRT, Department, Literature, Peptide, FDA, Isotope, RECIST, FAP, EANM, Kidney, Research, Security (finance), Cell, Trial of the century, Gallium, U.S. Securities and Exchange Commission, Radiation, Clovis Oncology, View, Sarcoma, Patient, Radiology, Gallbladder cancer, Drug discovery, Molecular Therapy, Toxicity, Safety, Biomedicine, Pharmaceutical industry, Medical imaging, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation at the 35th Annual European Association of Nuclear Medicine Congress (EANM) detailing updated Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary anti-tumor activity of its targeted radiotherapy candidate, FAP-2286 labeled with lutetium-177 (177Lu-FAP-2286).
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • The LuMIERE trial is the first prospective trial of a FAP peptide targeted radionuclide therapy and is currently in the dose escalation phase.
  • Updated results from the Phase 1 portion of the ongoing Phase 1/2 LuMIERE study found treatment-emergent adverse events (TEAEs) were mostly Grade 1 and 2 across cohorts.

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Wednesday, September 21, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Isotope, Half-life, Peptide, Nuclear pharmacy, Database administrator, Therapy, Safety, Radiation, Molecular imaging, Clovis Oncology, Sarcoma, FDA, FAP, SNMMI, Neoplasm, Antibody, Company, Population, Cancer, Private Securities Litigation Reform Act, Isotopia Festival, EANM, U.S. Securities and Exchange Commission, Program, Patient, Colon, CEO, Oncology, Gallium, Cell, Fibroblast, Radionuclide, NCT, NASDAQ, CAFS, Research, Security (finance), Congress, Mesothelioma, BD, GMP, EMA, View, Drug discovery, TRT, Pharmaceutical industry, Medical imaging

Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and Isotopia Molecular Imaging Ltd. today announced the signing of a clinical supply agreement that provides Clovis Oncology with Isotopias lutetium-177 (177Lu) n.c.a.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement further secures our ability to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.
  • Over the past four years, Isotopia has strengthened its supply chain to support the growing global demand and need for higher supply security, said Keren Moshkoviz, Deputy CEO and BD at Isotopia.

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Retrieved on: 
Tuesday, June 14, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Radiation, SNMMI, Clovis Oncology, Associate, Abdominal distension, Therapy, Isotope, PT, FAP, View, Cancer, RECIST, U.S. Securities and Exchange Commission, Mesothelioma, Sarcoma, Marnix, CEO, Society, Back pain, Pseudomyxoma peritonei, Trial of the century, Antibody, Clinical research coordinator, Colon, Population, Molecular imaging, University, Patient, Cell, EMA, Abstract, Security (finance), Gallium, Hyponatremia, CEA, Private Securities Litigation Reform Act, Research, Neoplasm, UCSF, University of California, San Francisco, Toxic leukoencephalopathy, FDA, Division, TRT, NASDAQ, SAE, Drug discovery, Peptide, Safety, Database administrator, Pharmaceutical industry, Vaccine, Medical imaging, Radiology, Pharmacokinetics

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) today announced an oral presentation detailing initial Phase 1 data from the Clovis Oncology-sponsored Phase 1/2 LuMIERE clinical study (NCT04939610) investigating the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of its targeted radiotherapy candidate, FAP-2286 labelled with lutetium-177 (177Lu-FAP-2286).
  • FAP-2286 is the first peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting FAP to enter clinical development and is the lead candidate in Clovis Oncologys targeted radionuclide therapy (TRT) development program.
  • The Phase 1 portion of the LuMIERE study is evaluating the safety of the investigational therapeutic agent 177Lu-FAP-2286 to identify the recommended Phase 2 dose and schedule.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).

Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

Retrieved on: 
Wednesday, May 4, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ASCO, Clovis Oncology, Sixth Street Partners, Population, PFS, Radiation, Maintenance, Woman, NASDAQ, LLC, Company, Research, GOG, Patient, ATHENA, Program, Nivolumab, Database administrator, SSP, CEO, ITT, Pharmaceutical industry, Medical imaging, Health insurance, Rucaparib

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2022, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.
  • Clovis expects research and development expenses in the full year 2022 to be comparable to 2021.
  • Net cash used in operating activities was $58.5 million for Q1 2022, down 5% from the $61.9 million reported in Q1 2021.
  • Clovis will hold a conference call this morning, May 4, at 8:30 am ET, to discuss Q1 2022 results and provide an update on the Companys clinical development programs and regulatory and commercial outlook.

Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting

Retrieved on: 
Friday, February 25, 2022
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Therapy, Gallium, Cell, Population, Peptide, Neoplasm, Molecular Therapy, IIT, Database administrator, American College, NASDAQ, Clovis Oncology, Radiation, University, Security (finance), Cancer, FAP, University of California, San Francisco, Antibody, UCSF, Private Securities Litigation Reform Act, Safety, Biomedicine, U.S. Securities and Exchange Commission, Trial of the century, Radiology, SNMMI, Isotope, TRT, View, Mesothelioma, FDA, EMA, Drug discovery, Patient, Sarcoma, CEO, Research, Society, Department, Colon, Medical imaging, Pharmaceutical industry, the LuMIERE Clinical Study, FAP-2286, Targeted Radionuclide Therapy, Clovis Oncology, THE LUMIERE CLINICAL STUDY, FAP-2286, TARGETED RADIONUCLIDE THERAPY, CLOVIS ONCOLOGY

Approximately 50 patients will be enrolled in the Phase 1 portion of the multicenter, open-label LuMIERE trial, which is currently enrolling patients with advanced solid tumors ( NCT04939610 ).

Key Points: 
  • Approximately 50 patients will be enrolled in the Phase 1 portion of the multicenter, open-label LuMIERE trial, which is currently enrolling patients with advanced solid tumors ( NCT04939610 ).
  • Once the Phase 2 therapeutic dose is determined, Phase 2 expansion cohorts in multiple tumor types are planned for later in 2022.
  • LuMIERE is a Phase 1/2 study evaluating FAP-2286 as a peptide-targeted radionuclide therapy (PTRT) targeting fibroblast activation protein, or FAP, in patients with advanced solid tumors.
  • FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP).

Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones

Retrieved on: 
Wednesday, February 23, 2022
Oncology, Health, Clinical Trials, Radiology, Pharmaceutical, Biotechnology, Risk, Cell, ATHENA, Peptide, ATM, Time, Security (finance), Radiation, COVID-19, Company, Form, PARP2, TRT, Clovis Oncology, Sarcoma, Private Securities Litigation Reform Act, BRCA, Nuclear medicine, Therapy, Growth, PFS, Research, PARP3, Safety, Nivolumab, SSP, LLC, U.S. Securities and Exchange Commission, Review, Q4, Mesothelioma, Disclosure, Maintenance, CEO, Program, Ovarian cancer, Gallium, Insurance, Population, Drug, Neoplasm, International, NASDAQ, Cancer, PARP1, FAP, Sixth Street Partners, Antibody, Mutation, Isotope, Peritonitis, EMA, Patient, Form 8-K, Colon, Annual report, Clinical trial, Adult, FDA, SEC, Pharmaceutical industry, Medical imaging, Liquor, Internet service provider, Rucaparib, Database administrator, MCRPC, Rubraca (rucaparib), FAP-2286, Targeted Radionuclide Therapy, Clovis Oncology, RUBRACA (RUCAPARIB), FAP-2286, TARGETED RADIONUCLIDE THERAPY, CLOVIS ONCOLOGY

Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) reported financial results for the quarter ended December 31, 2021, and provided an update on the Companys clinical development programs and regulatory and commercial outlook.
  • Clovis reported a net loss for Q4 2021 of $64.4 million, or ($0.50) per share, and a net loss of $264.5 million, or ($2.29) per share, for FY 2021.
  • Similarly, net cash used in operating activities for FY 2021 was $196.1 million, compared with $252.7 million for FY 2020.
  • The accompanying condensed consolidated financial results have been prepared on a basis which assumes that Clovis will continue as a going concern.

Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021

Retrieved on: 
Monday, January 10, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Exchange, Clinical trial, Safety, Cancer, Radiation, Form 8-K, Form, Gallium, PARP1, Colon, Neoplasm, View, Peritonitis, Database administrator, Drug, Security (finance), Antibody, Mutation, Patient, Isotope, Conference, Ovarian cancer, Adult, NASDAQ, Clovis Oncology, U.S. Securities and Exchange Commission, Insurance, BRCA, Peptide, Mesothelioma, Annual report, Program, PARP2, Rucaparib, Cell, CEO, Private Securities Litigation Reform Act, Company, FAP, Nuclear medicine, Sarcoma, PARP3, ATHENA, News, COVID-19, FDA, Therapy, Webcast, EMA, Population, Maintenance, Pharmaceutical industry, Medical imaging, Liquor, MCRPC, Rubraca (rucaparib), FAP-2286, Targeted Radionuclide Therapy, the LuMIERE Clinical Study, Clovis Oncology, RUBRACA (RUCAPARIB), FAP-2286, TARGETED RADIONUCLIDE THERAPY, THE LUMIERE CLINICAL STUDY, CLOVIS ONCOLOGY

Clovis Oncology , Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021.

Key Points: 
  • Clovis Oncology , Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited global product revenues for the fourth quarter and full year ended December 31, 2021.
  • The Company plans to report financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, February 23, 2022, before the open of the US financial markets.
  • Furthermore, we are in the process of finalizing our financial results for the fourth quarter and fiscal year 2021, and therefore our finalized and audited results and final analysis of those results are not yet available.
  • You should not draw any conclusions as to any other financial results as of and for the year ended December 31, 2021 based on the foregoing estimates.

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Retrieved on: 
Thursday, December 9, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, EMA, U.S. Securities and Exchange Commission, Translational medicine, Colon, Neoplasm, Population, Research, TRT, Therapy, Gallium, Security (finance), Peptide, Radiation, Drug discovery, Isotope, Safety, Private Securities Litigation Reform Act, Database administrator, Mesothelioma, Cancer, View, Radiopharmaceutical, FAP, Patient, CEO, Antibody, Clovis Oncology, Phase 1, FDA, NASDAQ, Sarcoma, Cell, Medical imaging, Pharmaceutical industry, FAP-2286, Targeted Radionuclide Therapy, the LuMIERE Clinical Study, Clovis Oncology, FAP-2286, TARGETED RADIONUCLIDE THERAPY, THE LUMIERE CLINICAL STUDY, CLOVIS ONCOLOGY

Clovis Oncology, Inc. (NASDAQ: CLVS) announced todays presentation by Andrew D. Simmons, Ph.D., Clovis Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals Summit being held virtually December 7-9, 2021.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) announced todays presentation by Andrew D. Simmons, Ph.D., Clovis Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals Summit being held virtually December 7-9, 2021.
  • We look forward to sharing initial data from the ongoing Phase 1 LuMIERE study of our first targeted radiotherapy candidate FAP-2286, anticipated in 2022.
  • For more information about FAP-2286, targeted radionuclide therapy, or Clovis TRT development program, please visit targetedradiotherapy.com .
  • Clovis Oncology undertakes no obligation to update or revise any forward-looking statements.

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Tuesday, October 19, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Peptide, Database administrator, EMA, Security (finance), Mesothelioma, Bone, ART, Patient, Radiopharmaceutical, Nuclear medicine, Safety, Drug discovery, Isotope, View, Private Securities Litigation Reform Act, Sarcoma, CAFS, Fibroblast, Leadership, Cancer, Population, Radionuclide, Cell, Antibody, Neoplasm, U.S. Securities and Exchange Commission, Lung, Colon, Breast cancer, Glioblastoma, FDA, Half-life, CEO, Trial of the century, FAP, NASDAQ, ITM, Wilms' tumor, TRT, Multimedia, Osteosarcoma, Program, Research, NCT, Radiation, Therapy, Clovis Oncology, Prostate cancer, Pharmaceutical industry, Medical imaging

ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.

Key Points: 
  • ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.
  • 177Lu), EndolucinBeta, for use in the clinical development of FAP-2286, Clovis fibroblast activation protein (FAP)-targeting therapeutic candidate.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement allows us to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.